Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Completed · Phase 2

Conditions studied: Prostate Cancer

In brief

RATIONALE: Vaccines made from a patient's white blood cells may make the body build an immune response to kill cancer cells. Interleukin-12 may kill cancer cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Combining vaccine therapy with interleukin-12 may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy combined with interleukin-12 in treating patients who have metastatic prostate cancer that has not responded to hormone therapy.

Key facts

Study ID

NCT00015977

Run by

University of Chicago

People needed

13

Starts

2001-11-01

Expected to finish

2005-01-01

Last updated by the study team

2014-03-07

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• University of Chicago Cancer Research Center — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.